Agios Pharm

NASDAQ AGIO

Data sourced from

and

Download Data

Agios Pharm Total Liabilities to Total Assets Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending March 31, 2024: 17.51%

Agios Pharm Total Liabilities to Total Assets Ratio 1 year YoY Change (%) is 17.51% for the Trailing 12 Months (TTM) ending March 31, 2024, a 32.07% change year over year. The total liabilities to total assets ratio measures the proportion of total liabilities to total assets. It is calculated by dividing the total liabilities by the total assets. This ratio provides insights into the company's financial leverage and the proportion of its assets financed by liabilities. A higher ratio indicates a higher level of financial risk and reliance on liabilities for asset acquisition. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Agios Pharm Total Liabilities to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.11, a 13.26% change year over year.
Agios Pharm Total Liabilities to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.09, a -75.18% change year over year.
Agios Pharm Total Liabilities to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.38, a 28.01% change year over year.
Agios Pharm Total Liabilities to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 0.29, a 46.89% change year over year.

NASDAQ: AGIO

Agios Pharm

CEO	Dr. Bruce D. Car DACVP, Ph.D.
IPO Date	July 24, 2013
Location	United States
Headquarters	88 Sidney Street, Cambridge, MA, United States, 02139-4169
Employees	383
Sector	Healthcare
Industry	Biotechnology

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Key trends